title: Use of monoclonal antibodies in vivo as a therapeutic strategy for acute GvHD in matched and mismatched bone marrow transplantation.
authors.affiliation: Bone Marrow Transplant Unit of Besançon, France.
authors.forename: P
authors.initials: P
authors.lastname: Herve
authors.forename: P
authors.initials: P
authors.lastname: Bordigoni
authors.forename: J Y
authors.initials: JY
authors.lastname: Cahn
authors.forename: M
authors.initials: M
authors.lastname: Flesch
authors.forename: P
authors.initials: P
authors.lastname: Tiberghien
authors.forename: E
authors.initials: E
authors.lastname: Racadot
authors.forename: N
authors.initials: N
authors.lastname: Milpied
authors.forename: J P
authors.initials: JP
authors.lastname: Bergerat
authors.forename: E
authors.initials: E
authors.lastname: Plouvier
authors.forename: C
authors.initials: C
authors.lastname: Roche
mesh_terms: D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D006086:Graft vs Host Disease / Q000628:therapy*; D006648:Histocompatibility; D006801:Humans; D010865:Pilot Projects; D015375:Receptors, Interleukin-2 / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D015375:Receptors, Interleukin-2; D014409:Tumor Necrosis Factor-alpha